Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon575 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49279 | 35803320 | Metabolism | Recent guidelines for non-alcoholic fatty liver disease (NAFLD): Are they already outdated and in need of supplementation? | 2022 | Details |
| A49360 | 35778847 | Lipids | Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease. | 2022 | Details |
| A49548 | 35718339 | Mol Metab | Hepatocyte cholesterol content modulates glucagon receptor signalling. | 2022 | Details |
| A49572 | 35709779 | Acta Gastroenterol Belg | Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ? | 2022 | Details |
| A49574 | 35709586 | Diabetes Metab Syndr | Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. | 2022 | Details |
| A49608 | 35693370 | Cureus | Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A49709 | 35662921 | Front Nutr | High Protein Diets Improve Liver Fat and Insulin Sensitivity by Prandial but Not Fasting Glucagon Secretion in Type 2 Diabetes. | 2022 | Details |
| A49718 | 35659603 | Clin Res Hepatol Gastroenterol | Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A49721 | 35657697 | Diabetes | Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1. | 2022 | Details |
| A49722 | 35657688 | Diabetes | The Liver-Alpha Cell Axis in Health and in Disease. | 2022 | Details |
| A49748 | 35650449 | Pharm Res | Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. | 2022 | Details |
| A49754 | 35646540 | Acta Pharm Sin B | Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. | 2021 | Details |
| A49802 | 35633911 | World J Gastroenterol | Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice. | 2022 | Details |
| A49813 | 35629915 | Metabolites | Renin-Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins. | 2022 | Details |
| A49829 | 35625757 | Biomedicines | Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A49962 | 35581956 | Hepatol Commun | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | 2022 | Details |
| A49988 | 35569886 | Endocr Pract | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). | 2022 | Details |
| A50123 | 35512974 | Fertil Steril | Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. | 2022 | Details |
| A50133 | 35508252 | Arch Biochem Biophys | Eugenol alleviated nonalcoholic fatty liver disease in rat via a gut-brain-liver axis involving glucagon-like Peptide-1. | 2022 | Details |
| A50136 | 35507280 | Curr Atheroscler Rep | Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. | 2022 | Details |
| A50153 | 35501557 | Curr Obes Rep | Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50166 | 35494531 | Diabetes Metab Syndr Obes | Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. | 2022 | Details |
| A50239 | 35462330 | Biomed Pharmacother | Update of Indoles: Promising molecules for ameliorating metabolic diseases. | 2022 | Details |
| A50241 | 35461369 | Sci Rep | Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. | 2022 | Details |
| A50298 | 35439567 | J Hepatol | Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50386 | 35409028 | Int J Mol Sci | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50648 | 35316465 | Curr Diab Rep | Implementation of Cardiometabolic Centers and Training Programs. | 2022 | Details |
| A50654 | 35312970 | Diabetes Ther | Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. | 2022 | Details |
| A50724 | 35286799 | Clin Mol Hepatol | Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A50788 | 35266164 | Aliment Pharmacol Ther | Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. | 2022 | Details |
| A50948 | 31402898 | Front Endocrinol (Lausanne) | Editorial: Gastrointestinal Hormones. | 2019 | Details |
| A51161 | 35427802 | Clin Res Hepatol Gastroenterol | The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice. | 2022 | Details |
| A51317 | 35674880 | Clin Pharmacokinet | Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. | 2022 | Details |
| A51332 | 35535116 | J Clin Exp Hepatol | An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. | 2021 | Details |
| A51388 | 30623143 | JACC Basic Transl Sci | The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. | 2018 | Details |
| A51396 | 35830001 | Drugs | Tirzepatide: First Approval. | 2022 | Details |
| A51412 | 35709720 | Semin Liver Dis | Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update. | 2022 | Details |
| A51416 | 35680133 | Drug Metab Dispos | In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. | 2022 | Details |
| A51536 | 35491295 | Trends Endocrinol Metab | SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A51617 | 35618993 | J Gastrointest Surg | Sleeve Gastrectomy Improves High-Fat Diet-Associated Hepatic Steatosis Independent of the Glucagon-like-Petpide-1 Receptor in Rats. | 2022 | Details |
| A51686 | 34920733 | Cardiovasc Diabetol | Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. | 2021 | Details |
| A51719 | 34629258 | Nutr Metab Cardiovasc Dis | Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. | 2021 | Details |
| A51772 | 34233623 | Cell Mol Biol Lett | Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. | 2021 | Details |
| A51777 | 34143451 | FASEB J | Holdemanella biformis improves glucose tolerance and regulates GLP-1 signaling in obese mice. | 2021 | Details |
| A51789 | 34064308 | Nutrients | Leptin Receptors Are Not Required for Roux-en-Y Gastric Bypass Surgery to Normalize Energy and Glucose Homeostasis in Rats. | 2021 | Details |
| A51795 | 34039937 | J Clin Gastroenterol | Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis. | 2021 | Details |
| A51872 | 33538983 | Obes Surg | Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery. | 2021 | Details |
| A51886 | 33455774 | J Dairy Sci | Relationships between metabolic profiles and gene expression in liver and leukocytes of dairy cows in early lactation. | 2021 | Details |
| A51991 | 32548470 | ACS Omega | Effects of Inulin Propionate Ester on Obesity-Related Metabolic Syndrome and Intestinal Microbial Homeostasis in Diet-Induced Obese Mice. | 2020 | Details |
| A52096 | 31307210 | FASEB J | Ileal interposition surgery targets the hepatic TGF-β pathway, influencing gluconeogenesis and mitochondrial bioenergetics in the UCD-T2DM rat model of diabetes. | 2019 | Details |
| A52109 | 31103416 | Biochem Pharmacol | Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice. | 2019 | Details |
| A52153 | 30619718 | J Clin Transl Endocrinol | Metabolic effects of glucagon in humans. | 2018 | Details |
| A52196 | 30212233 | Chronobiol Int | Timing of food intake is more potent than habitual voluntary exercise to prevent diet-induced obesity in mice. | 2018 | Details |
| A52279 | 29371333 | Eur J Endocrinol | MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? | 2018 | Details |
| A52289 | 29074588 | Arterioscler Thromb Vasc Biol | GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance. | 2017 | Details |
| A52370 | 28086952 | J Med Case Rep | Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. | 2017 | Details |
| A52475 | 26579439 | Acta Pharm Sin B | Bile acid nuclear receptor FXR and digestive system diseases. | 2015 | Details |
| A52477 | 26546347 | J Cardiovasc Magn Reson | Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. | 2015 | Details |
| A52501 | 26287659 | Int J Dev Neurosci | Short term exendin-4 treatment reduces markers of metabolic disorders in female offspring of obese rat dams. | 2015 | Details |
| A52528 | 25972231 | Diabetologia | Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice. | 2015 | Details |
| A52668 | 23886976 | Benef Microbes | Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. | 2014 | Details |
| A52710 | 23118444 | J Lipid Res | AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. | 2012 | Details |
| A52804 | 21549160 | Regul Pept | GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. | 2011 | Details |
| A52832 | 21151924 | PLoS One | Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. | 2010 | Details |
| A53080 | 15520626 | MedGenMed | Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. | 2004 | Details |
| A53096 | 15010338 | Am J Physiol Endocrinol Metab | Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. | 2004 | Details |
| A53097 | 14747292 | Diabetes | Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. | 2004 | Details |
| A53105 | 14507025 | J Dairy Sci | Effects of exogenous glucagon on lipids in lipoproteins and liver of lactating dairy cows. | 2003 | Details |
| A53155 | 9670624 | Indian J Pathol Microbiol | Observations on hepatic structure and function in fibro-calculous pancreatic diabetes (FCPD) vis-a-vis other diabetic subtypes. | 1998 | Details |
| A53179 | 2661933 | Mech Ageing Dev | Effect of chronic caloric restriction on hepatic enzymes of intermediary metabolism in the male Fischer 344 rat. | 1989 | Details |
| A53189 | 201171 | Am J Med | Corticosteroid-responsive skeletal muscle disease associated with partial carnitine deficiency: studies of liver and metabolic alterations. | 1977 | Details |
| A53192 | 1175860 | Diabetes | Metabolic studies in the pyelonephritic rat. | 1975 | Details |